AstraZeneca PLC thinks New Jersey-based Insmed Inc. has the necessary funding and expertise to successfully progress the novel oral inhibitor of dipeptidyl peptidase I (DPP1) dubbed AZD7986 in treating bronchiectasis, where the airways of the lungs become abnormally widened, leading to a build-up of excess mucus that can make the lungs more vulnerable to infection.
In its latest out-licensing exercise, AstraZeneca said it sold the rights to the experimental early-stage respiratory drug in a deal worth $150m. AstraZeneca will get $30m in upfront fees and $120m in various milestone payments
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?